Sen. Sheldon Whitehouse Purchases Shares of Guardant Health, Inc. (NASDAQ:GH)

Senator Sheldon Whitehouse (D-Rhode Island) recently bought shares of Guardant Health, Inc. (NASDAQ:GH). In a filing disclosed on December 01st, the Senator disclosed that they had bought between $1,001 and $15,000 in Guardant Health stock on November 21st.

Senator Sheldon Whitehouse also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 11/21/2025.
• Purchased $1,001 – $15,000 in shares of CocaCola (NYSE:KO) on 11/21/2025.
• Sold $15,001 – $50,000 in shares of Progressive (NYSE:PGR) on 10/27/2025.
• Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 10/20/2025.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 9/4/2025.
• Sold $1,001 – $15,000 in shares of Verizon Communications (NYSE:VZ) on 9/4/2025.
• Sold $15,001 – $50,000 in shares of UnitedHealth Group (NYSE:UNH) on 9/4/2025.
• Sold $15,001 – $50,000 in shares of Honeywell International (NASDAQ:HON) on 9/4/2025.
• Sold $15,001 – $50,000 in shares of Apple (NASDAQ:AAPL) on 9/4/2025.
• Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 9/4/2025.

Guardant Health Trading Down 3.0%

Shares of GH opened at $105.22 on Tuesday. The company’s fifty day simple moving average is $81.02 and its 200-day simple moving average is $61.58. The company has a market cap of $13.26 billion, a P/E ratio of -32.78 and a beta of 1.56. Guardant Health, Inc. has a twelve month low of $29.91 and a twelve month high of $112.43.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.09. The firm’s revenue for the quarter was up 38.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.88) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. Analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Guardant Health news, insider John G. Saia sold 8,996 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $96.25, for a total value of $865,865.00. Following the completion of the sale, the insider directly owned 43,172 shares in the company, valued at approximately $4,155,305. This trade represents a 17.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the firm’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the completion of the sale, the director directly owned 851 shares of the company’s stock, valued at approximately $46,090.16. This represents a 71.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 313,061 shares of company stock valued at $18,989,478. 6.10% of the stock is currently owned by insiders.

Institutional Trading of Guardant Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Signaturefd LLC lifted its position in shares of Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after buying an additional 213 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after acquiring an additional 334 shares in the last quarter. Allworth Financial LP lifted its position in Guardant Health by 358.4% during the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock valued at $37,000 after acquiring an additional 552 shares during the last quarter. Sound Income Strategies LLC purchased a new stake in Guardant Health during the third quarter valued at approximately $38,000. Finally, Optiver Holding B.V. boosted its stake in Guardant Health by 153.5% in the third quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock valued at $48,000 after acquiring an additional 465 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. BTIG Research upped their price target on shares of Guardant Health from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Canaccord Genuity Group set a $100.00 target price on shares of Guardant Health in a research note on Thursday, October 30th. Leerink Partners raised their target price on shares of Guardant Health from $70.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. Wells Fargo & Company initiated coverage on shares of Guardant Health in a research note on Monday, September 22nd. They set an “overweight” rating and a $72.00 price target for the company. Finally, Guggenheim increased their price objective on Guardant Health from $56.00 to $67.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.86.

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2031.

Whitehouse (Democratic Party) ran for re-election to the U.S. Senate to represent Rhode Island. He won in the general election on November 5, 2024.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.